Valeant sprints ahead of Endo to secure Salix
March 18, 2015Sales and Marketing Actavis, Canada, Endo, Valeant, Xifaxan, methylnaltrexone, rifaximin, salix
Salix Pharmaceuticals has accepted an improved $11.1 billion takeover swoop from Valeant Pharmaceuticals to beat rival bidder Endo International. The …
AstraZeneca buoyed by late-stage trial success
March 18, 2015Sales and Marketing AstraZeneca, copd. asthma, formoterol fumarate, glycopyrronium, ptoo3, respiratory
AstraZeneca’s investigational respiratory drug has posted positive results in a Phase III trial in people with COPD, having found it …
The 2015 European Life Sciences Industry Survey on Customer Data
March 18, 2015Dear Colleague, You are invited to take part in the 2015 European Life Sciences Industry Survey on Customer Data. Your …
GSK premature babies drug starts late-stage trials
March 18, 2015Sales and Marketing GSK, Retosiban, atosiban, babies, birth, oxytocin, premature
GlaxoSmithKline has initiated Phase III studies to evaluate the safety and efficacy of an investigational treatment for babies born prematurely. …
Catalent Pharma Solutions names new unit head
March 18, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing catalent pharma solutions, sharon johnson
UK pharma and healthcare products firm Catalent Pharma Solutions has picked its senior VP Sharon Johnson of the company’s quality …
Baxter’s haemophilia drug performs
March 17, 2015Sales and Marketing BAX 817, VIIa, baxter, haemophilia, rFVIIa
Baxter International has reported positive Phase III clinical trial results for its investigational haemophilia drug BAX 817. The recombinant factor VIIa …
Mixed results for AstraZeneca in high-profile Brilinta study
March 17, 2015Sales and Marketing American College of Cardiology, AstraZeneca, Brilinta, EMA, FDA, ticagrelor
Experts say AstraZeneca is at risk of ‘diminishing returns’ in the clinical advantages of its blood-thinning drug Brilinta, after it …
Novartis blood cancer drug given EU nod
March 17, 2015Sales and Marketing Cancer, EU, Jakavi, Novartis, oncology, polycythemia vera, ruxolitinib
Novartis’ blood cancer drug Jakavi has been given the green light in Europe to treat adult patients with polycythemia vera …
Sanofi affiliate to supply 37 million vaccines
March 17, 2015Manufacturing and Production, Sales and Marketing GAVI, Sanofi, Sanofi Pasteur, Shantha Biotechnics, shan5, vaccines
Sanofi’s vaccines division Sanofi Pasteur has confirmed its affiliate Shantha Biotechnics in India has delivered the first 400,000 doses of …
Big pharma partners with government over $100m dementia fund
March 17, 2015Research and Development, Sales and Marketing Alzheimer's, Biogen IDEC, GSK, J&J, JJ, Pfizer, government, jp morgan, lilly
Lilly, Pfizer, GSK, J&J and Biogen Idec are set to join a $100m Dementia Discovery Fund to boost research into …
23andMe assigns chief scientific officer to new unit
March 17, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 23andm3, Richard Scheller
US personal genetics firm 23andMe has created a new therapeutics group and appointed pharma veteran Richard Scheller as chief science …
23andMe to move into drug development
March 16, 2015Medical Communications, Research and Development, Sales and Marketing 23andME, DNA, Genentech, Pfizer, google
The Google-backed DNA test company 23andMe has announced plans to start using genetic data to design new drugs. In recent …
NHS is struggling to improve cancer care
March 16, 2015Sales and Marketing CRUK, Cancer, Department of Health, NHS, NHS England, oncology
The Department of Health and NHS England are struggling with the demand required to improve its cancer services according to …
Sanofi and Amgen cholesterol drugs shine
March 16, 2015Sales and Marketing Amgen, PCSK9, Repatha, Sanofi, alirocumab, evolocumab, praluent
Two large Phase III studies of Sanofi’s Praluent and Amgen’s Repatha have found the biologic cholesterol-lowering drugs are more effective …
Boehringer eyes Ofev success in IPF and beyond
March 16, 2015Sales and Marketing Boehringer, Esbriet, Roche, ingelheim, inpulsis, ipd, ofev
Experts say the launch of Boehringer Ingelheim’s new treatment for idiopathic pulmonary fibrosis (IPF) offers stiff competition to Roche’s Esbriet …
Drug development contracts: can lessons be learned from healthcare delivery?
March 16, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CCG, CRO, Les Rose, NHS, drug development, trials
There is a very good question to ask at the beginning of every project: “What does success look like?” If …
Recipharm appoints quality management VP
March 16, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Recipharm, thomas beck
Contract development and manufacturing organisation Recipharm has appointed Thomas Beck to the new senior role of vice president of quality …
Pharma pays £310 million underwriting UK meds bill
March 13, 2015Sales and Marketing ABPI, NHS, PPRS, body, department, health pricing, pharma
Pharma has made a fourth quarter payment of £81 million to underwrite the 2014 UK medicines bill under the Pharmaceutical …
BMS resubmits hepatitis C drug
March 13, 2015Sales and Marketing BMS, NDA, daclatasvir gilead, hepatitis C, sovaldi
Bristol-Myers Squibb has resubmitted its hepatitis C (HCV) treatment for FDA approval despite previously backing out, as it spots a …
Blow for Pfizer as Lyrica misses target
March 13, 2015Sales and Marketing FDA, Lyrica, Pfizer, fibromyalgia, pain, pregablin
A late-stage study of Pfizer’s Lyrica has failed to demonstrate it has any significant pain reduction in patients with fibromyalgia. …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
